XBI ETF holdings (NYSE) - Page 5 | MetaTrader

展开完整图表

概览所有持仓热图

主要持股 Market Value Shares Weight %

CLDX Celldex Therapeutics Inc 38.8 M 1.2 M 0.5%

NVAX Novavax Inc 38.0 M 4.7 M 0.5%

ORKA Oruka Therapeutics Inc 37.3 M 761.0 K 0.5%

OLMA Olema Pharmaceuticals Inc 36.9 M 2.5 M 0.5%

STOK Stoke Therapeutics Inc 36.7 M 1.1 M 0.5%

VCEL Vericel Corp 35.9 M 1.1 M 0.5%

CAPR Capricor Therapeutics Inc 35.6 M 1.2 M 0.5%

PVLA Palvella Therapeutics Inc 34.2 M 274.2 K 0.5%

BHVN Biohaven Ltd 32.5 M 3.8 M 0.4%

GLUE Monte Rosa Therapeutics Inc 32.4 M 2.0 M 0.4%

CRVS Corvus Pharmaceuticals Inc 31.0 M 2.1 M 0.4%

IOVA Iovance Biotherapeutics Inc 28.6 M 8.1 M 0.4%

ANAB AnaptysBio Inc 28.4 M 512.2 K 0.4%

RLAY Relay Therapeutics Inc 28.2 M 2.8 M 0.4%

QURE uniQure NV 27.8 M 1.7 M 0.4%

ORIC ORIC Pharmaceuticals Inc 27.5 M 2.2 M 0.4%

MNKD MannKind Corp 26.8 M 10.9 M 0.4%

CDNA CareDx Inc 25.7 M 1.5 M 0.3%

TSHA Taysha Gene Therapies Inc 25.2 M 5.6 M 0.3%

TYRA Tyra Biosciences Inc 25.1 M 655.5 K 0.3%

1
2
3
4
5
6
7
8

新闻

Gate 合约股票专区将上线 BOT（机器人策略封闭式基金）等 5 个永续合约交易

Oppenheimer维持Inovio制药"跑赢大盘"评级,关注加速审批途径

William Blair维持Compass Therapeutics增持评级,静待试验数据公布

Oppenheimer三月美股策略：动量策略正当时推荐苹果(AAPL.US)、美铝(AA.US)、贝克休斯(BKR.US)等个股

Citizens重申Ideaya Biosciences股票市场表现优于大盘评级

H.C. Wainwright上调Praxis Precision Medicines股票目标价至1,245美元

Oppenheimer重申Capricor股票"优于大盘"评级，维持54美元目标价

Oppenheimer上调Dianthus Therapeutics股票目标价至125美元，此前为62美元

派博桑德勒将Praxis Precision Medicines股票目标价上调至1,200美元

Roth/MKM 对 Arcturus Therapeutics 股票启动覆盖，给予"买入"评级

野村医疗股票获美银重申"跑赢大盘"评级

Wave Life Sciences股价在Arrowhead数据支持INHBE机制后上涨